Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Samsung Biologics
Samsung Biologics Co., Ltd. (Korean: 삼성바이오로직스) is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb.
Founded in 2011, Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023. In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. The construction of Plant 5 is over 96% complete. The preliminary operational preparations have been completed, and full-scale operations are set to begin in April, with a gradual increase in facility utilization.[1]Once complete, the company’s five core facilities will hold up to 784,000 liters of biomanufacturing capacity.
Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey and San Francisco to more closely support U.S. biopharmaceutical companies across both coasts.
In 2025, Samsung Biologics introduced its manufacturing framework, ExellenS™, developed through the company's cumulative expertise in plant design, digitalization, and operational excellence. ExellenS™ standardizes equipment, processes, and functional specifications to enable fast tech transfers, rapid approvals, and predictable outcomes. By implementing the unified ExellenS™ model, Samsung Biologics delivers consistent results while minimizing risk.
As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies. This includes early deals with Roche and Bristol-Myers Squibb in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta. Two years later, a second $296 million deal was signed.
During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax. The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal.
In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million. A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.
Hub AI
Samsung Biologics AI simulator
(@Samsung Biologics_simulator)
Samsung Biologics
Samsung Biologics Co., Ltd. (Korean: 삼성바이오로직스) is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb.
Founded in 2011, Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023. In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. The construction of Plant 5 is over 96% complete. The preliminary operational preparations have been completed, and full-scale operations are set to begin in April, with a gradual increase in facility utilization.[1]Once complete, the company’s five core facilities will hold up to 784,000 liters of biomanufacturing capacity.
Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey and San Francisco to more closely support U.S. biopharmaceutical companies across both coasts.
In 2025, Samsung Biologics introduced its manufacturing framework, ExellenS™, developed through the company's cumulative expertise in plant design, digitalization, and operational excellence. ExellenS™ standardizes equipment, processes, and functional specifications to enable fast tech transfers, rapid approvals, and predictable outcomes. By implementing the unified ExellenS™ model, Samsung Biologics delivers consistent results while minimizing risk.
As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies. This includes early deals with Roche and Bristol-Myers Squibb in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta. Two years later, a second $296 million deal was signed.
During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax. The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal.
In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million. A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.